Document:

Settlement  Agreement (Suros Surgical Systems)

 Exhibit 10.14 
 SETTLEMENT AGREEMENT 
 This Settlement Agreement is made and is effective as of this 22 day of May,
2006 (the “Effective Date”), by and between Suros Surgical Systems, Inc., having a place of business at 6100 Technology Center Drive, Indianapolis, Indiana, 46278 (“Suros”) and SenoRx, Inc., having a place of business at 11
Columbia, Suite A, Aliso Viejo, California, 92656 (“SenoRx”). Suros and SenoRx are referred to collectively as the “Parties” and individually as a “Party.” 
 WHEREAS, Suros filed suit against SenoRx in the United States District Court for the Southern District of Indiana, Cause No. 01:05-CV-00251-LJM-WTL
(the “Litigation”) claiming infringement of Suros’ United States Patent No. 5,997,560 (the “’560 Patent”); 
 WHEREAS, SenoRx has denied the infringement allegations raised by Suros in the Litigation and raised defenses of patent invalidity; and 
 WHEREAS, the Parties now wish to resolve the Litigation without any admission of liability on the part of any of the Parties with respect to the claims and defenses asserted in the Litigation; 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, it is hereby agreed between
and among the Parties that: 
  

	 	1.	SenoRx agrees to discontinue the making, using, importing, offering to sell and selling of a surgical instrument that employs a cutter design having a transverse slot (a physical
sample of such accused product was marked as Plaintiff’s Deposition Exhibit 20 – see Attachment 1 attached hereto) no later than October 31, 2006, and for as long as the ’560 patent remains in force. 

  

	 	2.	SenoRx agrees to have an officer or other authorized representative certify in writing to Suros that the conditions of Paragraph 1 have been met no later than the close of business
(PST) on October 31, 2006. Such certification shall be sent by facsimile and/or electronic mail to Kristin L. Murphy, Esq., Rader, Fishman & Grauer, 39533 Woodward Avenue, Suite 140, Bloomfield Hills, Michigan 48034 (Facsimile:
248.594.0610; Email: klm@raderfishman.com), with an original confirmation copy to follow via U.S. Mail or other mail provider. 

  

	 	3.	Within two (2) business days of the Effective Date, Suros agrees to dismiss the Litigation, without prejudice. To this end, each of the Parties agrees to execute the
Stipulation of Dismissal Without Prejudice that is attached hereto as Attachment 2. The terms and provisions are set forth in the Stipulation of Dismissal. The signed Stipulation of Dismissal shall be returned to counsel for Suros, along with a
fully executed original of this Confidential Settlement Agreement. Counsel for Suros shall cause the Stipulation of Dismissal to be filed with the Court. 

	 	4.	If SenoRx makes the certification described in Paragraph 2, Suros, its present and former officers, directors, employees, attorneys, and its and their successors and assigns,
including but not limited to any successor in interest to the ’560 patent, covenants and agrees that it will never institute or prosecute (or in any way aid any other person or entity in instituting or prosecuting), at law or in equity, any
claim, demand, action or cause of action for damages, costs, expenses or compensation, or for an enjoinment, injunction, or any other equitable remedy, against SenoRx, its present and former officers, directors, employees and attorneys, and its and
their successors and assigns, alleging infringement, including, without limitation, direct infringement, contributory infringement, or inducement of infringement, of the ’560 patent based on SenoRx’s manufacture, use, offer for sale, sale
or importation of any surgical instrument incorporating a cutter design as shown in Plaintiff’s Deposition Exhibit 43 or incorporating any cutter not having a transverse slot. 

  

	 	5.	If SenoRx makes the certification described in Paragraph 2, Suros, its present and former officers, directors, employees, attorneys, and its and their successors and assigns,
including but not limited to any successor in interest to the ’560 patent, releases, acquits, and forever discharges SenoRx, its present and former officers, directors, employees and attorneys, and its and their successors and assigns, from any
and all claims or causes of action, in law or in equity, demands, liabilities, losses, damages, costs, expenses, compensation, and all other damages and liabilities of any kind or nature whatsoever, direct or indirect, whether known or unknown,
suspected or unsuspected, choate or inchoate, that Suros, its present and former officers, directors, employees, attorneys, and its and their successors and assigns, including but not limited to any successor in interest to the ’560 patent,
ever had or now have for infringement, including, without limitation, direct infringement, contributory infringement, or inducement of infringement, of the ’560 patent based on SenoRx’s manufacture, use, offer for sale, sale or importation
of any surgical device that includes a cutter having a transverse slot (such as shown in Plaintiff’s Deposition Exhibit 20) that occurred at any time on or before October 31, 2006. This release does not extend to any acts that occur
subsequent to October 31, 2006. 

  

	 	6.	Should SenoRx fail to make the certification described in Paragraph 2, Suros may re-file the Litigation after October 31, 2006. 

  

	 	7.	In the event SenoRx makes the certification described in Paragraph 2, and either Party thereafter learns that SenoRx has, after making 

 such certification, sold to a third party a surgical instrument that employs a cutter design having a
transverse slot (a physical sample of such accused product was marked as Plaintiff’s Deposition Exhibit 20 – see Attachment 1 attached hereto)(hereinafter referred to as an “Unauthorized Sale”), the Party that learns of the sale
must notify the other Party in writing of each such Unauthorized Sale of which it is aware. If SenoRx learns of the Unauthorized Sale, it must notify Suros, in writing, of the Unauthorized Sale, including the quantity of such Unauthorized Sales,
within three (3) business days of learning of the Unauthorized Sale. If Suros learns of an Unauthorized Sale, Suros shall notify SenoRx in writing of each such sale of which it is aware. Within five (5) business days of receipt of such
notice from Suros or within five (5) business days of learning of an Unauthorized Sale itself, SenoRx shall replace each such surgical cutting instrument with a surgical instrument incorporating a cutter design not having a transverse slot
(such as shown in Plaintiff’s Deposition Exhibit 43) and shall certify in writing to Suros that the surgical cutting instruments that are the subject of such Unauthorized Sales have been replaced. Failure to replace the surgical cutting
instruments that are the subject of an Unauthorized Sale within five (5) business days constitutes a material breach of this Agreement. 
  

	 	8.	Suros, its present and former officers, directors, employees, attorneys, and its and their successors and assigns, including but not limited to any successor in interest to the
’560 patent, covenants and agrees that it will not at any time from the Effective Date to and including October 31, 2006, institute or prosecute (or in any way aid any other person or entity in instituting or prosecuting), at law or in
equity, any claim, demand, action or cause of action for damages, costs, expenses or compensation, or for an enjoinment, injunction, or any other equitable remedy, against SenoRx, its present and former officers, directors, employees and attorneys,
and its and their successors and assigns, alleging infringement, including, without limitation, direct infringement, contributory infringement, or inducement of infringement, of the ’560 patent related to any use, manufacture, importation,
sale, or offer for sale of a surgical device that includes a cutter having a transverse slot (such as shown in Plaintiff’s Deposition Exhibit 20). 

  

	 	9.	Nothing contained in this Settlement Agreement is an admission of any type in regard to the asserted claims and defenses in the Litigation. Each Party agrees further that neither
the existence of this Settlement Agreement nor the dismissal nor the release contained herein may be used in any proceeding as an admission or evidence of any liability owed by one Party to another, other than to enforce this Settlement Agreement.

	 	10.	Any Party may disclose or discuss the terms of this Settlement Agreement. 

  

	 	11.	Either of the Parties may, but is not required to, issue a public statement concerning the settlement of the Litigation. 

  

	 	12.	Neither the Parties nor their officers, directors, employees, servants, agents or attorneys shall make negative or disparaging comments or statements, whether oral or written, about
each other to any third party relating to the Litigation or this Settlement Agreement. Not withstanding for foregoing, the Parties may make factual, non-disparaging statements concerning the Litigation. 

  

	 	13.	The Parties (by and through their signatories below) each represent and warrant, on behalf of themselves and all those bound through them by this Settlement Agreement under
Paragraph 16, as follows: 

 (a) They are authorized to enter in this Settlement Agreement on behalf of
themselves and any other person whose consent is required hereunder or who may be bound hereby; 
 (b) They have complete
ownership of any claims released herein, and that no other party has any interest in such claims, except to the extent that the Parties are authorized to and do in fact release such claims herein on their behalf; 
 (c) This Settlement Agreement does not conflict with any other agreement and, to the best of their knowledge, with any law; 
 (d) The Parties have read this Settlement Agreement, consulted with their respective counsel prior to signing the Settlement Agreement,
and conducted whatever investigation they deem necessary, desirable or prudent, and they are not relying on any promise, representation or other agreement not expressly contained herein; and 
 (e) Suros owns all right, title and interest in and to the ’560 patent. 
  

	 	14.	This Settlement Agreement constitutes the entire understanding and agreement between the Parties and supersedes any and all prior agreements, proposals, understanding, negotiations
and discussion of the Parties. No amendment, supplement, modification, or waiver of this Settlement Agreement shall be binding unless executed in writing by duly authorized representatives of the Parties. 

  

	 	15.	If any term or provision of this Agreement is found to be invalid, illegal or unenforceable, the remainder of the provision will be amended to achieve as closely as possible the
economic effect of 

 the original term and the validity, legality, or enforceability of the remaining terms and provisions
will not in any way be affected or impaired thereby. 
  

	 	16.	This Settlement Agreement shall be binding on and benefit the Parties, their affiliates, owners, directors, officers, principals, employees, agents, representatives, attorneys,
heirs, successors, predecessors, and/or assigns, including but not limited to any successor in interest to the ’560 patent. 

  

	 	17.	Each Party shall bear its own costs, expenses, and attorneys’ fees in connection with the Litigation. However, nothing in this Agreement shall prevent Suros from seeking its
attorneys’ fees or other legal remedies in a second action against SenoRx should SenoRx fail to comply with its obligations described in Paragraph 1 and make the certification described in Paragraph 2, nor shall anything in this Agreement
create any right for Suros to seek such fees and other legal remedies. 

  

	 	18.	Upon filing the Stipulation of Dismissal as set forth in Paragraph 3, each Party will promptly comply with the provisions of the Protective Order entered in the Litigation with
regard to the destruction or return of the confidential information of any Party. All transcripts and audio or video recordings of depositions taken in the Litigation shall be treated, in their entirety, as “Confidential” within the
meaning of the Protective Order entered in the Litigation. Each Party, or its outside counsel, shall retain a copy of its own document production and discovery responses for at least one year after the Effective Date. 

  

	 	19.	The Parties agree that they have been represented by counsel during the negotiation and execution of this Agreement and that this Agreement was mutually drafted. Therefore, the
Parties waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting any such agreement or document. 

 

	 	20.	This Settlement Agreement may be executed in any number of counterparts, each of which shall be deemed an original, effective upon execution by the last Party to sign hereto. It is
agreed that the signature of any Party hereto transmitted via facsimile shall be fully binding and effective. 

  

	 	21.	The Parties shall cooperate fully to effectuate the provisions of this Settlement Agreement and its Attachments, including but not limited to, the preparation and execution of any
and all documents necessary to complete, carry out and enforce all the terms of this Settlement Agreement and Attachments. 

							
	ACCEPTED AND AGREED:	  		 	
		
	SUROS SURGICAL SYSTEMS, INC.	  	SENORX, INC.
				
	By:	 	/s/ Jim Pearson	  	    By:	 	/s/ Lloyd H. Malchow
				
	Title:	 	CEO & President	  	    Title:	 	President & CEO
				
	Date:	 	5\23\06	  	    Date:	 	5\22\06SERIES TERM CERTIFICATE

 Exhibit 4(a) 
 WAL-MART STORES, INC. 
 Series Terms Certificate  
 Pursuant to Section 3.01 of the Indenture 
 Pursuant to Section 3.01 of the Indenture, dated as of July 19, 2005 (the “Indenture”), made between Wal-Mart Stores, Inc., a Delaware corporation (the “Company”), and J.P. Morgan Trust Company, National
Association, as Trustee (the “Trustee”), Steven R. Zielske, Vice President, Finance and Assistant Treasurer of the Company, hereby certifies as follows, and Anthony D. George, Associate General Counsel, Finance and Assistant Secretary of
the Company, attests to the following certification. Any capitalized term used herein shall have the definition ascribed to that term as set forth in the Indenture unless otherwise defined herein. 
 A. This certificate is a Series Terms Certificate contemplated by Section 3.01 of the Indenture and is being executed to evidence the establishment
and approval of the terms and conditions of the Series that was established pursuant to Section 3.01 of the Indenture by means of a Unanimous Written Consent of the Executive Committee of the Board of Directors of the Company, dated
April 24, 2006 (the “Original Series Consent”), which Series is designated as the “1.78% Notes Due 2011” (the “2011 Series”), by Steven R. Zielske, Vice President, Finance and Assistant Treasurer of the Company,
pursuant to the grant of authority under the terms of the Original Series Consent. 
 B. Each of the undersigned has read the Indenture,
including the provisions of Sections 1.02 and 3.01 and the definitions relating thereto, and the resolutions adopted in the Original Series Consent. In the opinion of the undersigned, the undersigned have made such examination or investigation as is
necessary to enable the undersigned to express an informed opinion as to whether or not all conditions precedent provided for in the Indenture relating to the execution and delivery by the Trustee of the Indenture, to the creation, establishment and
approval of the title, the form and the terms of a Series under the Indenture, and to the authentication and delivery by the Trustee of promissory notes of a Series, have been complied with. In the opinion of the undersigned, (i) all such
conditions precedent have been complied with and (ii) there are no Events of Default, or events which, with the passage of time, would become an Event of Default under the Indenture that have occurred and are continuing at the date of this
certificate. 
 C. Pursuant to the Original Series Consent, the Company is authorized to issue ¥50,000,000,000 aggregate principal amount
of promissory notes of the 2011 Series (the “Initial Notes”). A copy of the Original Series Consent is attached hereto as Annex A. Any promissory notes that the Company issues that are a part of the 2011 Series (the
“Notes”) shall be represented by a global security substantially in the form attached hereto as Annex B (the “Form of Note”). 
 D. Pursuant to Section 3.01 of the Indenture, the terms and conditions of the 2011 Series and the promissory notes forming a part of the 2011 Series, including the Notes, are established and approved to be the
following: 

	 	1.	Designation: 

 The Series established by the
Original Series Consent is designated as the “1.78% Notes Due 2011”. 
  

	 	2.	Aggregate Principal Amount: 

 The 2011 Series is
not limited as to the aggregate principal amount of all the promissory notes of the 2011 Series that the Company may issue. The Company is issuing the Initial Notes, which have an aggregate original principal amount of ¥50,000,000,000.

  

	 	3.	Maturity: 

 Final maturity of the Notes of the 2011
Series will be May 26, 2011. 
  

	 	4.	Interest: 

  

	 	a.	Rate 

 The Notes will bear interest at the rate of
1.78% per annum, which interest shall commence accruing from and including May 26, 2006. Additional Amounts (as defined in Section 4(a) of the Form of Note), if any, will also be payable on the Notes. 
  

	 	b.	Payment Dates 

 Interest will be payable on the
Notes semi-annually in arrears on May 26 and November 26 of each year, beginning on November 26, 2006, to the person or persons in whose name or names the Notes are registered at the close of business on the immediately preceding
May 15 or November 15, as the case may be. Interest on the Notes will be computed on the basis of the actual number of days in the relevant interest period and a year of 365 days. 
  

	 	5.	Currency of Payment: 

 The principal and interest
payable with respect to the Notes shall be payable in Japanese yen. 
  

	 	6.	Payment Places: 

 All payments of principal of and
interest on the Notes shall be made as set forth in Section 5 of the Form of Note. 
  

 2 

	 	7.	Optional Redemption Features: 

 The Company may
redeem the Notes upon the occurrence of certain tax events pursuant to Section 4(b) of the Form of Note. 
 There is no sinking fund
with respect to the Notes. 
  

	 	8.	Special Redemption Features, etc.: 

 None.

  

	 	9.	Denominations: 

 ¥10,000,000 and integral
multiples of ¥1,000,000 for the Notes. 
  

	 	10.	Principal Repayment: 

 100% of the principal amount
of the Notes. 
  

	 	11.	Registrar, Paying Agent and Transfer Agent: 

 J.P.
Morgan Trust Company, National Association will be the registrar, U.S. paying agent and U.S. transfer agent for the Notes. JPMorgan Chase Bank, N.A., London Branch will be the London paying agent and the London transfer agent for the Notes. JPMorgan
Bank (Ireland) PLC will be the Irish paying agent and Irish transfer agent for the Notes 
  

	 	12.	Payment of Additional Amounts: 

 The Company shall
pay additional amounts as set forth under Section 4(a) of the Form of Note. 
  

	 	13.	Book-Entry Procedures: 

 The Notes shall be issued
in the form of a single global note registered in the name of Chase Nominees Limited, as the nominee of JPMorgan Chase Bank, N.A., London Branch, as common depositary (the “Common Depositary”) for Clearstream Banking,
société anonyme and Euroclear Bank S.A./N.V., and will be issued in certificated form only in limited circumstances, in each case, as set forth under Sections 11 and 12 of the Form of Note. 
  

	 	14.	Other Terms: 

 Sections 2, 3, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16 and 17 of the Form of Note attached hereto as Annex B shall also apply to the Notes. 
  

 3 

 The Notes will not have any terms or conditions of the type contemplated by clause (ii), (iii), (vi),
(vii), (xii), (xiii), (xvi), (xvii), or (xx) of Section 3.01 of the Indenture. 
 E. The Notes will be issued pursuant to and
governed by the Indenture. To the extent that the Indenture’s terms apply to the Notes specifically or apply to the terms of all Securities of all Series established pursuant to and governed by the Indenture, such terms shall apply to the
Notes. 
  

 4 

 IN WITNESS WHEREOF, the undersigned has hereunto executed this Certificate as of May 19,
2006. 
  

	
	
	 /s/ Steven R. Zielske

	 Steven R. Zielske

	 Vice President of Finance and Assistant Treasurer

  

	
	ATTEST:
	
	 /s/ Anthony D. George

	 Anthony D. George

	 Associate General Counsel, Finance

	 and Assistant Secretary

 ANNEX A 
 UNANIMOUS CONSENT TO ACTION 
 IN LIEU OF SPECIAL MEETING 
 OF THE EXECUTIVE COMMITTEE OF 
 THE
BOARD OF DIRECTORS 
 OF WAL-MART STORES, INC. 
 April 24, 2006 
  

 The undersigned, being all of the members of the Executive Committee of the Board of Directors of Wal-Mart Stores, Inc., a Delaware corporation (the
“Company”), do hereby consent to the adoption of the following resolutions in accordance with the provisions of Section 141(f) of the General Corporation Law of Delaware: 
 WHEREAS, the Company has registered with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended, and the rules
promulgated thereunder, the offer and sale of an indeterminate amount of its debt securities, which debt securities are to be issued pursuant to the terms of the Indenture, dated as of July 19, 2005 (the “Indenture”), between the
Company and J.P. Morgan Trust Company, National Association, as trustee (the “Indenture Trustee”), in one or more offerings; and 
 WHEREAS, the Company desires to sell in an underwritten public offering (the “Offering”) its debt securities denominated in Japanese Yen and having an aggregate principal amount not to exceed ¥50,000,000,000.

 RESOLVED, that a series of senior, unsecured promissory notes of the Company in an initial aggregate principal amount not to exceed
¥50,000,000,000, that shall mature in 2011 on the fifth anniversary of the issuance of such notes (the “Series 2011 Notes”) shall be, and it hereby is, created, established and authorized for issuance and sale pursuant to the terms of
the Indenture; and 
 RESOLVED, that the Series 2011 Notes shall have such terms, including the rate at which interest will accrue on
the Series 2011 Notes, and shall be in such form as shall be established and approved by one or more of the Chairman of the Board of Directors, the Chief Executive Officer, any Vice Chairman, the Chief Financial Officer, any Executive Vice
President, any Senior Vice President, any Vice President, the Controller and the Treasurer of the Company (each an “Authorized Officer”) in accordance with the provisions of Section 3.01 of the Indenture pursuant to the authority
granted by these resolutions, which approval will be conclusively evidenced by that Authorized Officer’s or those Authorized Officers’ execution of a Series Terms Certificate (as defined in the Indenture) with respect to the Series 2011
Notes; and 
 RESOLVED, that the Authorized Officers shall be, and each of them hereby is, authorized, in the name and on behalf of
the Company, to establish and to approve the terms and conditions of the Series 2011 Notes, to set the aggregate principal amount of the Series 2011 Notes to be sold in the Offering and to approve the form, terms and conditions of the promissory
notes representing notes in the Series 2011 Notes (the “2011 Promissory Notes”); and 

 RESOLVED, that the Authorized Officers shall be, and each of them hereby is, authorized, in the
name and on behalf of the Company, to execute 2011 Promissory Notes having an aggregate principal amount not to exceed ¥50,000,000,000, all as provided in the Indenture, and to deliver those 2011 Promissory Notes to the Indenture Trustee for
authentication and delivery in accordance with the terms of the Indenture; and 
 RESOLVED, that the Indenture Trustee shall be, and
it hereby is, authorized and directed to authenticate and deliver up to ¥50,000,000,000 aggregate principal amount of 2011 Promissory Notes to or upon the written order of the Company, as provided in the Indenture; and 
 RESOLVED, that the Company shall be, and it hereby is, authorized to perform its obligations under the 2011 Promissory Notes issued and sold by
the Company and its obligations under the Indenture, as those obligations relate to those 2011 Promissory Notes; and 
 RESOLVED, that
the Company shall be, and it hereby is, authorized to enter into, execute and deliver, and perform its obligations under, and each Authorized Officer is authorized to execute and deliver, for and on behalf of the Company, a Pricing Agreement and an
Underwriting Agreement (collectively, the “Underwriting Agreement”) between the Company and Lehman Brothers Inc., Goldman, Sachs & Co. and any other underwriters named therein (collectively, the “Underwriters”),
providing for the sale by the Company and the purchase by the Underwriters of 2011 Promissory Notes having an aggregate principal amount not to exceed ¥50,000,000,000, which aggregate principal amount of such 2011 Promissory Notes shall be
determined by one or more Authorized Officers, such determination to be evidenced by the execution and delivery of the Underwriting Agreement by an Authorized Officer on behalf of the Company and any other agreements necessary to effectuate the
intent of these resolutions, the Underwriting Agreement and any other such agreements to be in the forms and to contain the terms, including the price to be paid to the Company by the Underwriter for the 2011 Promissory Notes being purchased
pursuant to the Underwriting Agreement, and conditions that the Authorized Officer executing the same approves, such approval to be conclusively evidenced by that Authorized Officer’s execution and delivery of the Underwriting Agreement or
other agreement; and 
 RESOLVED, that the Company shall be, and it hereby is, authorized to sell the 2011 Promissory Notes to the
Underwriters pursuant to the Underwriting Agreement at the price set forth in, and pursuant to the other terms and conditions of, the Underwriting Agreement; and 
 RESOLVED, that the Company shall be, and it hereby is, authorized to issue one or more global certificates to represent the 2011 Promissory Notes authorized in accordance with these resolutions and not
otherwise issue the 2011 Promissory Notes in definitive form, and to permit each global certificate representing 2011 Promissory Notes to be registered in the name of a nominee of The Depository Trust Company (“DTC”) and/or a nominee of
Clearstream Banking, S.A., Luxembourg (“Clearstream”) and Euroclear Bank, S.A./N.V. (“Euroclear”) and beneficial interests in the global certificates representing the 2011 Promissory Notes to be otherwise shown on, and transfers
of such beneficial interests effected through, records maintained by DTC and/or Clearstream and Euroclear and their respective participants; and 

 RESOLVED, that the signatures of the Authorized Officers executing any 2011 Promissory Note may be
the manual or facsimile signatures of the present or any future Authorized Officers and may be imprinted or otherwise reproduced thereon, and any such facsimile signature shall be binding upon the Company, notwithstanding the fact that at the time
the 2011 Promissory Notes are authenticated and delivered and disposed of, the person signing the facsimile signature shall have ceased to be an Authorized Officer; and 
 RESOLVED, that the Company shall be, and it hereby is, authorized to enter into, execute and deliver, and perform its obligations under, and each Authorized Officer is authorized to execute and deliver, for and
on behalf of the Company, an Interest Rate Swap Agreement relating to the 2011 Promissory Notes (the “Swap Agreement”), such Swap Agreement to be in the form, to be as to such notional amount and to contain such other terms and conditions
that the Authorized Officer executing the same approves, such approval to be conclusively evidenced by that Authorized Officer’s execution and delivery of such Swap Agreement; and 
 RESOLVED, that, without in any way limiting the authority heretofore granted to any Authorized Officer, the Authorized Officers shall be, and each
of them singly is, authorized and empowered to do and perform all such acts and things and to execute and deliver, for and on behalf of the Company, any and all documents and instruments and to take any and all such actions as they may deem
necessary, desirable or proper in order to carry out the intent and purpose of the foregoing resolutions and fully to establish the Series 2011 Notes and to perform the provisions of the Underwriting Agreement, the Indenture, the 2011 Promissory
Notes and the Swap Agreement, and to incur on behalf of the Company all such expenses and obligations in connection therewith as they may deem proper. 
 Dated this 24th day of April, 2006. 
  

					
		 		 	
			
	 /s/ David D. Glass
	 		 	 /s/ S. Robson Walton

	 David D. Glass
	 		 	 S. Robson Walton

			
	 /s/ H. Lee Scott, Jr.
	 		 	 
	 H. Lee Scott, Jr.
	 		 	

 ANNEX B—Form of Global Note 
 This Note is a global security and is registered in the name of Chase Nominees Limited, as nominee of the common depositary, JPMorgan Chase Bank, N.A.,
London Branch (the “Common Depositary”), for Clearstream Banking, société anonyme (“Clearstream”) and Euroclear Bank S.A./N.V. (“Euroclear”). Unless and until this Note is exchanged in whole or in
part for Notes in definitive form, this Note may not be transferred except as a whole by the Common Depositary or a nominee of the Common Depositary to the Common Depositary or another depositary or by the Common Depositary or a nominee of the
Common Depositary to a successor depositary or a nominee of such successor depositary. 
 WAL-MART
STORES, INC. 
 1.78% NOTES DUE 2011 
  

					
	 Number 1
 ¥50,000,000,000
	 		  	 ISIN No.: XS0255425174
 Common Code:
025542517

 WAL-MART STORES, INC., a corporation duly organized and existing under the laws of the State of
Delaware, and any successor corporation pursuant to the Indenture (herein referred to as the “Company”), for value received, hereby promises to pay to CHASE NOMINEES LIMITED or registered assigns, the principal sum of FIFTY BILLION YEN
(¥50,000,000,000) on May 26, 2011 in such coin or currency of Japan as at the time of payment shall be legal tender for the payment of public and private debts, and to pay interest, computed on the basis of the actual number of days in the
period and a year of 365 days, semi-annually in arrears on May 26 and November 26 of each year, or if any such day is not a Business Day, on the next succeeding Business Day (each, an “Interest Payment Date”), commencing on
November 26, 2006, on said principal sum in like coin or currency, at the rate per annum specified in the title of this Note from May 26, 2006 or from the most recent May 26 or November 26 to which interest has been paid or duly
provided for. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will be paid to the person in whose name this Note is registered (the “holder”) at the close of business on the preceding
May 15, in the case of an Interest Payment Date of May 26, and on the preceding November 15, in the case of an Interest Payment Date of November 26 (each, a “Record Date”). The term “Business Day” means any
day, other than a Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions are generally authorized or required by law or regulation to close in Tokyo, The City of New York or London. 
 Reference is made to the further provisions of this Note set forth on the succeeding sections hereof. Such further provisions shall for all purposes have
the same effect as though fully set forth at this place. 

 2 
  

 This Note shall not be valid or become obligatory for any purpose until the certificate of
authentication hereon shall have been signed by the Trustee under the Indenture referred to in Section 1 hereof. 
 IN WITNESS WHEREOF,
the Company has caused this instrument to be signed by its Chairman of the Board, its Vice Chairman, its President or one of its Vice Presidents and by its Secretary or one of its Assistant Secretaries, each by manual or facsimile signature and
under its corporate seal. 
  

									
		 		 	WAL-MART STORES, INC.
					
		 		 		 	By:	 	  
		 		 		 		 	Name:
		 		 		 		 	Title:
				
	[SEAL]	 		 	By:	 	  
		 		 		 		 	Name:
		 		 		 		 	Title:
		 		 		 		 	

 Dated: May 26, 2006 
 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 
 This is one of the Securities of the
Series designated herein referred to in the within-mentioned Indenture. 
  

									
		 		 	J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee
					
		 		 		 	By:	 	  
		 		 		 		 	Authorized Signatory

 WAL-MART STORES, INC. 
 1.78% NOTES DUE 2011 
 1. Indenture; Notes. This Note is one of a duly authorized series of
Securities of the Company designated as the “1.78% Notes Due 2011” (the “Notes”), initially issued in an aggregate principal amount of ¥50,000,000,000 on May 26, 2006. Such series of Securities has been established
pursuant to, and is one of an indefinite number of series of debt securities of the Company, issued or issuable under and pursuant to, the Indenture, dated as of July 19, 2005 (the “Indenture”), duly executed and delivered by the
Company, as Issuer, and J.P. Morgan Trust Company, National Association, as Trustee (the “Trustee”), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the rights, limitations of rights,
obligations, duties and immunities thereunder of the Trustee, the Company and the Holders of the Notes and of the terms upon which this Note is, and is to be, authenticated and delivered. The terms, conditions and provisions of the Notes are those
stated in the Indenture, those made part of the Indenture by reference to the Trust Indenture Act of 1939, as amended, and those set forth in this Note. To the extent that the terms, conditions and other provisions of this Note modify, supplement or
are inconsistent with those of the Indenture, then the terms, conditions and other provisions of this Note shall govern. 
 All capitalized
terms which are used but not defined in this Note shall have the meanings assigned to them in the Indenture. 
 The Company may, without the
consent of the Holders, create and issue additional Securities ranking equally with the Notes and otherwise identical in all respects (except for their date of issue, issue price and the date from which interest payments thereon shall accrue) so
that such additional Securities shall be consolidated and form a single series with the Notes; provided, however, that no additional Securities of any existing or new series may be issued under the Indenture if an Event of Default has
occurred and remains uncured thereunder. 
 2. Ranking. The Notes shall constitute the senior unsecured debt obligations of the
Company and shall rank equally in right of payment among themselves and with all other existing and future senior unsecured debt obligations of the Company. 
 3. Payment of Overdue Amounts. The Company shall pay interest, calculated on the basis of the actual number of days in the period and a year of 365 days, on overdue principal and overdue installments of
interest, if any, from time to time, on demand at the interest rate borne by the Notes to the extent lawful. 
 4. Payment of Additional
Amounts; Redemption Upon a Tax Event. 
 (a) Payment of Additional Amounts. The Company shall pay to the holder (including, for
purposes of this Section 4, each beneficial owner) of this Note who is a Non-U.S. Person (as defined below) additional amounts as may be necessary so that every net payment of principal of and interest on this Note to such holder, after
deduction or withholding for or on account of any present or future tax, assessment or other governmental charge imposed upon such holder by the United States or any taxing authority thereof or therein, will not be less than 

 2 
  

 
the amount provided in this Note to be then due and payable (such amounts, the “Additional Amounts”); provided, however, that the Company
shall not be required to make any payment of Additional Amounts for or on account of: 
 (i) any tax, assessment or other governmental charge
that would not have been imposed but for (A) the existence of any present or former connection between such holder, or between a fiduciary, settlor, beneficiary of, member or shareholder of, or possessor of a power over, such holder, if such
holder is an estate, trust, partnership or corporation, and the United States including, without limitation, such holder, or such fiduciary, settlor, beneficiary, member, shareholder or possessor, being or having been a citizen or resident of the
United States or treated as a resident thereof or being or having been engaged in trade or business or present in the United States, or (B) the presentation of this Note for payment on a date more than 30 days after the later of (x) the
date on which such payment becomes due and payable and (y) the date on which payment thereof is duly provided for; 
 (ii) any estate,
inheritance, gift, sales, transfer, excise, personal property or similar tax, assessment or other governmental charge; 
 (iii) any tax,
assessment or other governmental charge imposed on foreign personal holding company income or by reason of such holder’s past or present status as a passive foreign investment company, a controlled foreign corporation, a personal holding
company or foreign personal holding company with respect to the United States, or as a corporation that accumulates earnings to avoid United States federal income tax; 
 (iv) any tax, assessment or other governmental charge which is payable otherwise than by withholding from payment of principal of or interest on this Note; 
 (v) any tax, assessment or other governmental charge required to be withheld by any paying agent from any payment of principal of or interest on this
Note if such payment can be made without withholding by any other paying agent; 
 (vi) any tax, assessment or other governmental charge
which would not have been imposed but for the failure to comply with certification, information, documentation or other reporting requirements concerning the nationality, residence, identity or connections with the United States of the holder, if
such compliance is required by statute or by regulation of the U.S. Treasury Department as a precondition to relief or exemption from such tax, assessment or other governmental charge; 
 (vii) any tax, assessment or other governmental charge imposed on interest received by (A) a 10% shareholder (as defined in
Section 871(h)(3)(B) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), and the regulations that may be promulgated thereunder) of the Company or (B) a controlled foreign corporation with respect to the Company
within the meaning of the Code; 
 (viii) any withholding or deduction that is imposed on a payment to an individual and is required to be
made pursuant to that European Union Directive relating to the taxation of savings adopted on June 3, 2003 by the European Union’s Economic and Financial 

 3 
  

 
Affairs Council, or any law implementing or complying with, or introduced in order to conform to, such Directive; or 
 (ix) any combination of items (i), (ii), (iii), (iv), (v), (vi), (vii) and (viii) in this Section 4(a); 
 nor shall any Additional Amounts be paid to any holder who is a fiduciary or partnership to the extent that a beneficiary or settlor with respect to such fiduciary, or a
member of such partnership or a beneficial owner thereof, would not have been entitled to the payment of such Additional Amounts had such beneficiary, settlor, member or beneficial owner been the holder. 
 The term “Non-U.S. Person” means any corporation, partnership, individual or fiduciary that is, as to the United States, a foreign corporation,
a non-resident alien individual who has not made a valid election to be treated as a United States resident, a non-resident fiduciary of a foreign estate or trust, or a foreign partnership one or more of the members of which is, as to the United
States, a foreign corporation, a non-resident alien individual or a non-resident fiduciary of a foreign estate or trust. 
 (b) Redemption
Upon a Tax Event. The Notes may be redeemed at the option of the Company in whole, but not in part, on a date (such date, the “Tax Redemption Date”) to be fixed by the Company on not more than 60 days’ and not less than 30
days’ notice, at a redemption price equal to 100% of the principal amount of the Notes (the “Redemption Price”) plus accrued but unpaid interest, if any, and any Additional Amounts thereon, if the Company determines that as a result
of any change in or amendment to the laws, treaties, regulations or rulings of the United States or any political subdivision or taxing authority thereof, or any proposed change in such laws, treaties, regulations or rulings, or any change in the
official application, enforcement or interpretation of such laws, treaties, regulations or rulings, including a holding by a court of competent jurisdiction in the United States, or any other action, other than an action predicated on laws generally
known on or before May 19, 2006 except for proposals before the U.S. Congress before such date, taken by any taxing authority or a court of competent jurisdiction in the United States, or the official proposal of any action, whether or not such
action or proposal was taken or made with respect to the Company, (A) the Company has or will become obligated to pay Additional Amounts or (B) there is a substantial possibility that the Company will be required to pay such Additional
Amounts. 
 Prior to the publication of any notice of redemption pursuant to Section 15 hereof, the Company shall deliver to the Trustee
(1) an Officers’ Certificate stating that the Company is entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to the rights of the Company to so redeem have occurred and
(2) an Opinion of Counsel to such effect based on such statement of facts. 
 If the Company elects to redeem the Notes pursuant to this
Section 4(b), then it shall give notice to the holders pursuant to Section 15 hereof. 
 The notice of redemption, shall specify
the following: 
 (i) the Tax Redemption Date; 

 4 
  

 (ii) a brief statement to the effect that the Notes are being redeemed at the option of the Company
pursuant to this Section 4(b) and a brief statement of the facts permitting such redemption; 
 (iii) that on the Tax Redemption Date,
the Redemption Price, plus accrued but unpaid interest on the Notes, if any, will become due and payable and that interest thereon shall cease to accrue on and after such Tax Redemption Date; 
 (iv) the amount of the Redemption Price and accrued but unpaid interest, if any, that will be due and payable on the Notes on the Tax Redemption Date;

 (v) the place or places where the Notes are to be surrendered for payment of the Redemption Price and other amounts due under clause
(iv) above; 
 (vi) that payment of the amounts due under clause (iv) above will be made upon presentation and surrender of the
Notes; and 
 (vii) the ISIN and Common Code numbers of the Notes. 
 The notice of redemption regarding the Notes shall be, at the election of the Company, given by the Company or, at the Company’s request, by the
Trustee in the name and at the expense of the Company. 
 On or before the opening of business on any Tax Redemption Date, the Company shall
deposit with the Trustee or with the Paying Agent (or, if the Company is acting as its own paying agent, segregate and hold in trust as provided in Section 5.03 of the Indenture) an amount of money sufficient to pay the Redemption Price of, and
except if the Tax Redemption Date shall be an Interest Payment Date, accrued but unpaid interest on, the Notes to be redeemed on the Tax Redemption Date. 
 The notice of redemption having been given as specified above, the Notes shall, on the Tax Redemption Date, become due and payable at the Redemption Price, and from and after such date, unless the Company shall
default in the payment of the Redemption Price and accrued but unpaid interest, if any, the Notes shall cease to bear interest. Upon surrender of the Notes for redemption in accordance with such notice, the Notes shall be paid by the Company at the
Redemption Price, together with accrued but unpaid interest, if any, to the Tax Redemption Date. 
 If the Notes, having been called for
redemption, shall not be so paid upon surrender thereof for redemption, the Redemption Price shall, until paid, bear interest from the Tax Redemption Date at the interest rate borne by this Note. 
 5. Place and Method of Payment. The Company shall pay principal (and Redemption Price, if any) of and interest on the Notes at the office or
agency of the U.S. Paying Agent in the Borough of Manhattan, The City of New York and of the London Paying Agent in London and, for so long as the Notes are listed on the Irish Stock Exchange, of the Irish Paying Agent in Dublin, Ireland;
provided, however, that at the option of the Company, the Company 

 5 
  

 
may pay interest by check mailed to the person entitled thereto at such person’s address as it appears on the Registry for the Notes. 
 6. Defeasance of the Notes. Sections 11.02, 11.03 and 11.04 of the Indenture shall apply to the Notes. 
 7. No Redemption; Sinking Fund. The Notes are not redeemable prior to maturity, other than as set forth in Section 4(b) hereof, and are not
subject to a sinking fund. 
 8. Amendment and Modification. Article Nine of the Indenture contains provisions for the amendment or
modification of the Indenture and the Notes without the consent of the Holders in certain circumstances and requiring the consent of Holders of not less than a majority in aggregate principal amount of the Notes and Securities of other series that
would be affected in certain other circumstances. However, the Indenture requires the consent of each Holder of the Notes and Securities of other series that would be affected for certain specified amendments or modifications of the Indenture and
the Notes. These provisions of the Indenture, which provide for, among other things, the execution of supplemental indentures, are applicable to the Notes. 
 9. Event of Default; Acceleration of Maturity; Rescission and Annulment. If an Event of Default with respect to the Notes shall occur and be continuing, then the aggregate principal amount of the Notes of this
series may be declared by either the Trustee or the Holders of not less than 25% in aggregate principal amount of the Notes of this series then Outstanding to be, and, in certain cases, may automatically become, immediately due and payable in the
manner, with the effect and subject to the conditions provided in the Indenture. The Indenture provides that, in the event of such an acceleration of the maturity of the Notes, the Holders of a majority in aggregate principal amount of all of the
Notes of this series then Outstanding, voting as a separate class, in accordance with the provisions of, and in the circumstances provided by, the Indenture, may rescind and annul such acceleration and its consequences with respect to all of the
Notes. 
 10. Absolute Obligation. No reference herein to the Indenture and no provisions of the Notes or of the Indenture shall alter
or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and interest on this Note at the place, at the time and in the coin or currency herein prescribed. 
 11. Form and Denominations; Global Note; Definitive Notes. The Notes are being issued in registered form without interest coupons in denominations
of ¥10,000,000 and integral multiples of ¥1,000,000 in excess thereof. The Notes are being issued in the form of a single global note (the “Global Note”), evidencing all or any portion of the Notes and registered in the name of
Chase Nominees Limited, as nominee of the Common Depositary (including its respective successors) under the Indenture. The Notes shall be issued in certificated form (each, a “Definitive Note”) only in the following limited circumstances:
(1) the Common Depositary is at any time unwilling or unable to continue as the Common Depositary, or Clearstream Banking, société anonyme or Euroclear Bank S.A./N.V. ceases to be a clearing agency registered under
applicable law, and a successor Common Depositary is not appointed by the Company or a successor clearing agency satisfactory to the Company is not established within 90 days after the 

 6 
  

 
Company receives notice thereof; (2) the Company delivers to the Trustee a Company Order to the effect that this Note shall be exchangeable for
Definitive Notes; or (3) an Event of Default has occurred and is continuing with respect to the Notes, in each such case this Note shall be exchangeable for Definitive Notes in an equal aggregate principal amount. Such Definitive Notes shall be
registered in such name or names as the Common Depositary shall instruct the Trustee. 
 12. Registration, Transfer and Exchange. As
provided in the Indenture and subject to certain limitations therein set forth, the Company shall provide for the registration of the Notes and the transfer and exchange of the Notes, whether in global or definitive form. At the option of the
Holders, at the offices of the U.S. Transfer Agent, the London Transfer Agent or, so long as the Notes are listed on the Irish Stock Exchange, the Irish Transfer Agent (each as defined in Section 14 hereof), or at any of such other offices or
agencies as may be designated and maintained by the Company for such purpose pursuant to the provisions of the Indenture, and in the manner and subject to the limitations provided in the Indenture, but without the payment of any service charge,
except for any transfer tax or other governmental charges imposed in connection therewith subject to Section 4 hereof, the Notes may be transferred or exchanged for an equal aggregate principal amount of the Notes of like tenor and of other
authorized denominations upon surrender and cancellation of the Notes upon any such transfer. 
 The Company, the Trustee and any agent of
the Company or of the Trustee may deem and treat the holder as the absolute owner of this Note (whether or not the Notes shall be overdue and notwithstanding any notation of ownership or other writing hereon), for the purpose of receiving payments
hereon, or on account hereof, and for all other purposes, and neither the Company nor the Trustee nor any agent of the Company or of the Trustee shall be affected by any notice to the contrary. All such payments made to or upon the order of such
holder shall, to the extent of the amount or amounts paid, effectually satisfy and discharge liability for moneys payable on this Note. 
 Notwithstanding the preceding paragraphs of this Section 12, any registration of transfer or exchange of a Global Note shall be subject to the terms of the legend appearing on the initial page thereof. 
 13. No Recourse Against Others. No recourse under or upon any obligation, covenant or agreement of the Company arising under or set forth in the
Notes or under the Indenture, or for any claim based thereon or otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, as such, past, present or future, of the Company or of any successor corporation,
either directly or through the Company or any successor corporation, whether by virtue of any constitution, statute or rule of law or by the enforcement of any assessment or penalty or otherwise, any and all such personal liability, either at common
law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director, as such, being, by the acceptance hereof and as part of the consideration for the issue
hereof, expressly waived and released. 
 14. Appointment of Agents. J.P. Morgan Trust Company, National Association is hereby
appointed the registrar for the purpose of registering the Notes and transfers and exchanges of the Notes pursuant to the Indenture and this Note (the “Registrar”), 

 7 
  

 
paying agent pursuant to Section 3.04 of the Indenture (the “U.S. Paying Agent”) and transfer agent (the “U.S. Transfer Agent”) with
respect to the Notes in the United States at its offices in the Borough of Manhattan, The City of New York. 
 JPMorgan Chase Bank, N.A.,
London Branch is hereby appointed paying agent pursuant to Section 3.04 of the Indenture (the “London Paying Agent”) and transfer agent (the “London Transfer Agent”) with respect to the Notes in the United Kingdom at its
offices in London. 
 JPMorgan Bank (Ireland) PLC has been appointed, in connection with the listing of the Notes on the Irish Stock
Exchange, paying agent pursuant to Section 3.04 of the Indenture (the “Irish Paying Agent”), and transfer agent (the “Irish Transfer Agent”) with respect to the Notes in Ireland at its offices in Dublin, Ireland. 

If for any reason JPMorgan Bank (Ireland) PLC shall not continue as Irish Paying Agent or Irish Transfer Agent, and the Notes remain listed on the
Irish Stock Exchange, the Company shall appoint a substitute Irish Paying Agent or Irish Transfer Agent, as the case may be, with an office in Ireland, in accordance with the rules then in effect of the Irish Stock Exchange and the provisions of the
Indenture, including Section 3.04 thereof, and the Notes. Following the appointment of the substitute Irish Paying Agent or Irish Transfer Agent, as the case may be, the Company shall give the Holders of the Notes notice of such appointment
pursuant to Section 15 hereof. 
 15. Notices. If the Company is required to give notice to the Holders of the Notes pursuant to
the terms of the Indenture, then it shall do so by the means and in the manner set forth in Section 1.06 of the Indenture. 
 In
addition, the Company shall give notices to the Holders of the Notes by publication in a leading daily newspaper in The City of New York and in Tokyo and, so long as the Notes are listed on the Irish Stock Exchange, in Ireland. Initially, such
publication shall be made in The City of New York in The Wall Street Journal, in Tokyo in The Nikkei Financial Daily and in Ireland in the Irish Times. Any such notice shall be deemed to have been given on the date of
publication or, if published more than once, on the date of the first publication. 
 16. Separability. In case any provision of the
Indenture or the Notes shall, for any reason, be held to be invalid, illegal or unenforceable, then the validity, legality and enforceability of the remaining provisions thereof and hereof shall not in any way be affected or impaired thereby.

 17. GOVERNING LAW. THE NOTES SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 

 ASSIGNMENT FORM 
 To assign this Note, fill in the form below: 
 For the value received, the undersigned hereby assigns and transfers the
within Note, and all rights thereunder, to: 
  

 (Insert assignee’s legal name) 
  

 (Insert assignee’s social security or tax identification number) 
  

 (Print or type
assignee’s name, address and zip code) 
  

  

 

 and
irrevocably appoints 
                                       
                                        
                                        
                                        
                                        
                                        
                
 to transfer this Note on the books of Wal-Mart Stores, Inc. The
agent may substitute another to act for it. 
  

			
	 Your Signature:
	  	  

		  	(Sign exactly as your name appears on the face of this Note)

  

	
	 Date:
                                        
                                  

	 Signature Guarantee

 The signature(s) should be Guaranteed by an Eligible Guarantor Institution pursuant to Rule 17Ad-15 of the
Securities Exchange Act of 1934, as amended. 
 *    *    *    *    * 
 The following
abbreviations, when used in the inscription on the face of the within Note, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

			
	TEN COM -	 	as tenants in common
		
	TEN ENT -	 	as tenants by the entireties
		
	JT ENT -	 	 as joint tenants with right
 of survivorship and not
as
 tenants in common

  

													
	                                      
                 	 	 UNIF GIFT MIN ACT -
	 	  	  	Custodian	 	  	 	under the Uniform Gifts to Minors Act	 	  
		 		 	(Cust)	  		 	(Minor)	 		 	(State)

 Additional abbreviations may also be used although not in the above list.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]